Sector News

Ablynx Appoints Johan Heylen as Chief Commercial Officer

November 18, 2014
Life sciences
(GLOBE NEWSWIRE) – Ablynx today announced the appointment of Johan Heylen as Chief Commercial Officer. Mr Heylen will assume responsibility for all Ablynx’s commercial activities. He has more than 20 years of experience in global biopharmaceutical sales, marketing and business development at GlaxoSmithKline (GSK), Servier and Wyeth.
 
Most recently, Mr Heylen was Executive Director, Global Commercial Lead, Cancer Immunotherapeutics, at GSK, where he headed the global commercial teams and was responsible for the development and implementation of the launch strategy for GSK’s cancer immunotherapeutics portfolio. Prior to that, Mr Heylen led and launched the successful global commercial and marketing efforts for three of GSK’s paediatric vaccines, Rotarix®, Priorix® and Varilix®, which together achieved sales of more than €1.5 billion. He has experience in a wide range of therapeutic fields.
 
Welcoming Mr Heylen to the team, Dr Edwin Moses, CEO of Ablynx, said:
 
“Johan joins Ablynx as Chief Commercial Officer at an important stage in our development as a biopharmaceutical company. His extensive commercial experience with some of the world’s leading companies will help Ablynx to maximise the potential of our pipeline as our programmes move through the clinic and towards the market. He will also bring valuable expertise to our business development team as we seek to develop our relationships with pharmaceutical companies around the world.”
 
Commenting on his appointment, Mr Heylen added:
 
“Ablynx has an extraordinary pipeline of products based on its unique Nanobody® discovery platform, validated by an impressive list of partners. I look forward to working with the first-class team to support the company as it moves to the next stage of development and begins to anticipate the commercialisation of the first Nanobody-based therapeutics.”
 
Source: Ablynx

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach